Prospective TFA intake & The Rotterdam Study database derived energy intake, standard deviation dementia N= 5395, 41%M from the intake of increase in TFA intake: Age: 67.7 (≥55)y TRANSFAIR Study vitamin E 0.90 (95% CI 0.77 to 16y FU and Dutch Food 1.06), 197 dx Composition Table TFA intake (g/day): 2.7 ± 1.0 () Total TFA Country: Germany TFA in Fatty acids in maternal Serum: +ve assoc TTFA in N= 55, mother-child erythrocytes and and foetal plasma (% maternal plasma Cross-sectional Distribution pairs plasma: of total FAME, m ± SD) correlated with TTFA in of TFA in Age: mothers 29.2y t9t12, c9t12, **TTFA maternal 0.59 foetal plasma but not foetal cord t9c12, C18:2; ± 0.12; foetal: 0.52 ± adjusted for any blood t3,c9,c11 & 0.17 **r=0.36 confounders related to c8,t10,t12 C18:3 **C9,t11 CLA maternal were summarised maternal 0.20 ± 0.07; lipids as TTFA foetal: 0.14 ± 0.04 r=0.84 Collected at Fatty acids in maternal and foetal erythrocytes (% of total FAME, m ± SD) **TTFA maternal 0.82 ± 0.15; foetal: 0.64 ± 0.45 **r=0.07 **C9,t11 CLA maternal 0.12 ± 0.04; foetal: 0.08 ± 0.04 **r=0.32 () Individual Country: Germany Serum TFA: Comparison **Pts with Alzheimer’s Serum: +ve assoc TFA N= 60, 28%M gas among groups disease had vaccenic acid and Age: 70y chromatography done for gender, significantly higher Alzheimer’s disease Case-control Individual Cases: 30 age, educational intakes C18:1 (n-7) FTA & mild Controls:30 level and global vaccenic compared
Prospective TFA intake & dementia The Rotterdam Study N= 5395, 41%M Age: 67.7 (≥55)y 16y FU 197 dx TFA intake (g/day): 2.7 ± 1.0 database derived from the TRANSFAIR Study and Dutch Food Composition Table energy intake, intake of vitamin E standard deviation increase in TFA intake: 0.90 (95% CI 0.77 to 1.06), () Cross-sectional Total TFA Distribution of TFA in foetal cord blood related to maternal lipids Country: Germany N= 55, mother-child pairs Age: mothers 29.2y TFA in erythrocytes and plasma: t9t12, c9t12, t9c12, C18:2; t3,c9,c11 & c8,t10,t12 C18:3 were summarised as TTFA Collected at Fatty acids in maternal and foetal plasma (% of total FAME, m ± SD) **TTFA maternal 0.59 ± 0.12; foetal: 0.52 ± 0.17 **r=0.36 **C9,t11 CLA maternal 0.20 ± 0.07; foetal: 0.14 ± 0.04 r=0.84 Fatty acids in maternal and foetal erythrocytes (% of total FAME, m ± SD) **TTFA maternal 0.82 ± 0.15; foetal: 0.64 ± 0.45 **r=0.07 **C9,t11 CLA maternal 0.12 ± 0.04; foetal: 0.08 ± 0.04 **r=0.32 Serum: +ve assoc TTFA in maternal plasma correlated with TTFA in foetal plasma but not adjusted for any confounders () Case-control Individual TFA Individual FTA & mild Country: Germany N= 60, 28%M Age: 70y Cases: 30 Controls:30 Serum TFA: gas chromatography Comparison among groups done for gender, age, educational level and global **Pts with Alzheimer’s disease had significantly higher intakes C18:1 (n-7) vaccenic compared Serum: +ve assoc vaccenic acid and Alzheimer’s disease
Appendix%201%20to%20SD4%20Summary%20of%20reviewed%20literature%20examining%20TFA%20and%20health%20outcomes.docx